Abstracts Archive - Page 165 of 1683 - ATC Abstracts

2022 American Transplant Congress
Clinical Impact of a Modified Lung Allocation Score That Mitigates Selection Bias
E. M. Schnellinger¹, E. Cantu², D. E. Schaubel¹, S. E. Kimmel³, A. J. Stephens-Shields¹
¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Florida, Gainesville, FL
*Purpose: The U.S. lung allocation system uses the Lung Allocation Score (LAS) to prioritize lung transplant candidates. Selection bias, induced by dependent censoring of waitlisted…
2022 American Transplant Congress
HLA-DQ Mismatches Are More Likely to Be Listed as Unacceptable Antigens After Renal Graft Failure in African American Recipients as Compared to Other Racial/Ethnic Groups
D. Isaacson¹, M. W. Gmeiner², V. Kosmoliaptsis³, J. D. Schold⁴, A. R. Tambur¹
¹Northwestern University, Chicago, IL, ²London School of Economics, London, United Kingdom, ³Cambridge University, Cambridge, United Kingdom, ⁴Cleveland Clinic, Cleveland, OH
*Purpose: Growing evidence suggests that donor-recipient mismatches at the HLA-DQ locus are the most immunogenic and pathogenic, evidenced by generation of DQ donor-specific antibodies (DSA).…
2022 American Transplant Congress
Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States
A. Cerise¹, T. Shaker¹, K. Ramanathan¹, S. Jackson², R. Kandaswamy¹, S. Riad³
¹Surgery, University of Minnesota, Minneapolis, MN, ²Analytics, MHealth-Fairview, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN
*Purpose: Induction immunosuppression choice for simultaneous pancreas-kidney (SPK) transplants varies widely in the United States. We examined the association between induction agents and outcomes of…
2022 American Transplant Congress
Favorable Outcomes in Older Diabetics Receiving a Simultaneous Kidney Pancreas Transplant Compared to Those Receiving a Living Donor Kidney Transplant
P. Budhiraja¹, H. Me¹, J. Ninan², S. Reddy², S. S. Misra¹, R. Heilman¹, H. Khamash¹, K. Reddy¹, C. Jadloweic¹, N. Katariya¹, H. Chakkera¹
¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic, Rochester, MN
*Purpose: To compare the long-term outcomes of older (50-65 yr) diabetic patients who received Simultaneous Kidney pancreas transplantation (SKP) vs. living donor (LD) kidney transplants.*Methods:…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA Across the Spectrum of Solid Organ Transplantation
S. R. Potter¹, J. Miles², K. Qu², R. Woodward², S. Dholakia²
¹Baylor Scott & White Health, Temple, TX, ²CareDx, Inc, Brisbane, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a robust and clinically useful analyte initially validated for kidney allograft surveillance. Emerging data support the utility of dd-cfDNA…
2022 American Transplant Congress
TNFRSF13B Genotype Determines the Properties of Donor-Specific B Cells
M. Cascalho¹, M. Garcia de Mattos Barbosa¹, T. Pasieka¹, E. Farkash², R. Sung³, M. Doshi⁴, J. Platt⁴
¹Surgery, University of Michigan, Ann Arbor, MI, ²Pathology, University of Michigan, Ann Arbor, MI, ³University of Michigan Health System, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI
*Purpose: The TNFRSF13B gene is among the 5% most polymorphic genes in humans. The phenotypes of the most frequent TNFRSF13B variants in humans and mice…
2022 American Transplant Congress
National Consortium Registry Insights on Management and Outcome of Hepatitis C Viremic Heart Transplants
R. Gottlieb¹, M. Salem¹, A. Ravichandran², J. Kennedy³, J. Strope⁴, S. Lin⁵, J. Chow⁶, P. Eckman⁷, S. Desai⁸, O. Larkins¹, J. Vanzyl¹, S. Hall¹
¹Baylor Scott & White Healthcare, Dallas, TX, ²Ascension Medical Group, Indianapolis, IN, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Washington Medical Center, Seattle, WA, ⁶Tufts Medical Center, Boston, MA, ⁷Minneapolis Heart Institute, Minneapolis, MN, ⁸Ochsner Medical Center, New Orleans, LA
*Purpose: Multicenter US registry of clinical management of HCV NAT+ hearts.*Methods: An ongoing 8-center retrospective IRB-approved registry collected baseline characteristics, labs, management, and outcomes after…
2022 American Transplant Congress
New Oral Anticoagulants vs Warfarin in Kidney Transplant
S. R. Raslan¹, D. Alkortas²
¹Pharmaceutical Care, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²KFSH & RC, Riyadh, Saudi Arabia
*Purpose: New oral anticoagulants (NOACs) have replaced warfarin due to their similar efficacy and better safety profile in the general population (GP). The risk of…
2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
P. A. Jacobson¹, A. Saqr¹, M. Al-Kofahi¹, D. P. Schladt², W. Guan³, W. S. Oetting¹, R. Mannon⁴, C. R. Dorr⁵, R. P. Remmel¹, G. C. Onyeaghala⁶, B. Wu³, A. K. Israni⁷, A. Matas⁸
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Hennepin Health Research Institute, Minneapolis, MN, ³Univ of MN, Biostatistics, Minneapolis, MN, ⁴Univ of Nebraska, Dept of Medicine, Omaha, NE, ⁵Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, ⁶Hennepin Healthcare Research Institute, Minneapolis, MN, ⁷Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, ⁸University of MN, Dept of Surgery, Minneapolis, MN
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…